Page last updated: 2024-08-21

thiazoles and dactolisib

thiazoles has been researched along with dactolisib in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Auberger, P; Aumann, K; Braun, S; Brummer, T; Daly, RJ; Halbach, S; Laßmann, S; Pahl, HL; Penninger, JM; Schramek, D; Schwemmers, S; Waller, CF; Werner, M; Wöhrle, FU; Zeiser, R1
Ishikawa, D; Matsumoto, K; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S1
Fu, W; Hu, L; Zhu, W1
Ito, TK; Kadariya, Y; Pei, J; Sementino, E; Tan, Y; Testa, JR1
Alfieri, RR; Ardizzoni, A; Bonelli, MA; Caffarra, C; Cavazzoni, A; Cretella, D; Falco, A; Frati, C; Fumarola, C; Galetti, M; La Monica, S; Lagrasta, CA; Madeddu, D; Petronini, PG; Quaini, F; Rossetti, P; Saccani, F; Tiseo, M1
Baxter, RC; Pavlakis, N; Smith, RC; Wong, MH; Xue, A1
Chen, B; Kraus, D; Palasuberniam, P1

Other Studies

7 other study(ies) available for thiazoles and dactolisib

ArticleYear
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Leukemia, 2013, Volume: 27, Issue:1

    Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MAP Kinase Signaling System; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinolines; RNA, Small Interfering; Thiazoles; TOR Serine-Threonine Kinases; Tumor Cells, Cultured

2013
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
    International journal of cancer, 2013, Jul-15, Volume: 133, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, SCID; Mutation; Neoplasm Transplantation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Tetrazolium Salts; Thiazoles; TOR Serine-Threonine Kinases; Treatment Outcome

2013
NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3.
    Cancer biotherapy & radiopharmaceuticals, 2013, Volume: 28, Issue:9

    Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Flow Cytometry; Humans; Imidazoles; Male; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Quinolines; Radiation Tolerance; Radiation, Ionizing; Radiopharmaceuticals; Receptors, Androgen; Tetrazolium Salts; Thiazoles; TOR Serine-Threonine Kinases

2013
Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.
    Cancer biology & therapy, 2015, Volume: 16, Issue:4

    Topics: Animals; Apoptosis; Azepines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Everolimus; Homeodomain Proteins; Imidazoles; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Mice; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Quinolines; Signal Transduction; Thiazoles; Transcription, Genetic; Triazoles; Vincristine

2015
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:8

    Topics: Aminopyridines; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Epithelial-Mesenchymal Transition; Humans; Imidazoles; Lung Neoplasms; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinolines; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays

2015
Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Neoplasia (New York, N.Y.), 2016, Volume: 18, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Flavonoids; Humans; Imidazoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinolines; Thiazoles; TOR Serine-Threonine Kinases

2016
Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy.
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:11

    Topics: Aminopyridines; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Endothelial Cells; Humans; Imidazoles; Mice; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Recurrence, Local; Neoplasms; Neovascularization, Pathologic; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Photochemotherapy; Porphyrins; Protein Kinase Inhibitors; Quinolines; Signal Transduction; Thiazoles; Verteporfin; Xenograft Model Antitumor Assays

2017